FDA approves Alembic's Ticagrelor Tablets, 60 mg
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
Diltiazem works by relaxing blood vessels, which reduces the workload on the heart and increases blood and oxygen supply to the heart muscle
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound pressure waves to treat arterial calcium blockages
Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto® Tablets, 2.5 mg of Janssen Pharmaceuticals
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
Strokes are affecting approximately 1.8 million people annually
Dyslipidemia is a critical risk factor for cardiovascular diseases
Subscribe To Our Newsletter & Stay Updated